[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Moves -0.32%: What You Should Know",
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=8f06883526649461badb7f73955f380e8f58aa7c8008b7f370055269a75dfbc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736289919,
      "headline": "AbbVie (ABBV) Stock Moves -0.32%: What You Should Know",
      "id": 132315862,
      "image": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=8f06883526649461badb7f73955f380e8f58aa7c8008b7f370055269a75dfbc6"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=c41879d954a508a23e6cd2ade308baed410137c2313e5f023233cdf510d57b61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736269814,
      "headline": "Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?",
      "id": 132305357,
      "image": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=c41879d954a508a23e6cd2ade308baed410137c2313e5f023233cdf510d57b61"
    }
  },
  {
    "ts": null,
    "headline": "AOD: This 14.10%-Yielder May Face Headwinds In 2025, But Has Strong Finances",
    "summary": "The abrdn Total Dynamic Dividend Fund has a high yield, but watch out for lagging performance and valuations in its holdings. Click for my AOD update.",
    "url": "https://finnhub.io/api/news?id=130a397f0874b06e6b4511aa6b78a989b85c9972a162f6011c1e69ccbb45900d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736269558,
      "headline": "AOD: This 14.10%-Yielder May Face Headwinds In 2025, But Has Strong Finances",
      "id": 132307038,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302522750/image_1302522750.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The abrdn Total Dynamic Dividend Fund has a high yield, but watch out for lagging performance and valuations in its holdings. Click for my AOD update.",
      "url": "https://finnhub.io/api/news?id=130a397f0874b06e6b4511aa6b78a989b85c9972a162f6011c1e69ccbb45900d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=65997c1f6e6a8f7ab37c05a28fb091c3e3c3059cddba1f17c1cb936b0423c57f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736267640,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 132322048,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=65997c1f6e6a8f7ab37c05a28fb091c3e3c3059cddba1f17c1cb936b0423c57f"
    }
  },
  {
    "ts": null,
    "headline": "CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the number one non-surgical fat reduction treatment providers use most.1",
    "url": "https://finnhub.io/api/news?id=8bd496a88bb17f2efb4e119791d92b953ef85d5a816a1caf7bddf6d36c9b0df4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736254800,
      "headline": "CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics",
      "id": 132302098,
      "image": "https://media.zenfs.com/en/prnewswire.com/d07e572eaef73a27c1ae25977c221fa1",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the number one non-surgical fat reduction treatment providers use most.1",
      "url": "https://finnhub.io/api/news?id=8bd496a88bb17f2efb4e119791d92b953ef85d5a816a1caf7bddf6d36c9b0df4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs",
    "summary": "ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.",
    "url": "https://finnhub.io/api/news?id=874c06a933347f8aeece6363b7ff175c0a0cdaf1bb9af144ca962d204d2ca502",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736250660,
      "headline": "AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs",
      "id": 132302100,
      "image": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.",
      "url": "https://finnhub.io/api/news?id=874c06a933347f8aeece6363b7ff175c0a0cdaf1bb9af144ca962d204d2ca502"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  }
]